



US010415027B2

(12) **United States Patent**
White et al.

(10) **Patent No.:** **US 10,415,027 B2**
(45) **Date of Patent:** **Sep. 17, 2019**

(54) **TREATMENT FOR AIRWAY CAST OBSTRUCTION**

FOREIGN PATENT DOCUMENTS

WO WO 2004/058186 7/2004

(71) Applicant: **NATIONAL JEWISH HEALTH,**
Denver, CO (US)

OTHER PUBLICATIONS

(72) Inventors: **Carl W. White,** Denver, CO (US);
Livia A. Veress, Denver, CO (US)

Allon et al. "Inhalation exposure to sulfur mustard in the guinea pig model: Clinical, biochemical and histopathological characterization of respiratory injuries," *Toxicology and Applied Pharmacology*, Dec. 2009, vol. 241, No. 2, pp. 154-162.

(73) Assignee: **National Jewish Health,** Denver, CO (US)

American College of Emergency Physicians and American Academy of Neurology "Clinical Policy: Use of Intravenous tPA for the Management of Acute Ischemic Stroke in the Emergency Department," *Annals of Emergency Medicine*, Feb. 2013, vol. 61, No. 2, pp. 225-243.

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 215 days.

Anderson et al. "Pathologic Changes in Rat Lungs Following Acute Sulfur Mustard Inhalation," *Inhalation Toxicology*, 1996, vol. 8, pp. 285-297.

(21) Appl. No.: **14/649,238**

Balali-Mood et al. "Comparison of Early and Late Toxic Effects of Sulfur Mustard in Iranian Veterans," *Basic & Clinical Pharmacology & Toxicology*, Oct. 2006, vol. 99, No. 4, pp. 273-282.

(22) PCT Filed: **Dec. 5, 2013**

Costello et al. "Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature." *Pediatrics*, Apr. 2002, vol. 109, No. 4, pp. e67.

(86) PCT No.: **PCT/US2013/073372**

§ 371 (c)(1),

(2) Date: **Jun. 3, 2015**

Graham et al. "Historical perspective on effects and treatment of sulfur mustard injuries," *Chemico-Biological Interactions*, Dec. 2013, vol. 206, No. 3, pp. 512-522.

(87) PCT Pub. No.: **WO2014/089327**

PCT Pub. Date: **Jun. 12, 2014**

Heath et al. "Prospective, Longitudinal Study of Plastic Bronchitis Cast Pathology and Responsiveness to Tissue Plasminogen Activator (tPA)." *Pediatric Cardiology*, Dec. 2011, vol. 32, No. 8, pp. 1182-1189.

(65) **Prior Publication Data**

US 2015/0322421 A1 Nov. 12, 2015

Jugg et al. "N-acetyl-L-cysteine protects against inhaled sulfur mustard poisoning in the large swine," *Clinical Toxicology*, May 2013, vol. 51, No. 4, pp. 216-224.

Related U.S. Application Data

Rancourt et al. "Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation," *Toxicology and Applied Pharmacology*, Oct. 2013, vol. 272, No. 1, pp. 86-95.

(60) Provisional application No. 61/733,798, filed on Dec. 5, 2012.

Rancourt et al. "Airway tissue factor-dependent coagulation activity in response to sulfur mustard analog 2-chloroethyl ethyl sulfide," *American Journal of Physiology Lung Cellular and Molecular Physiology*, Jan. 2012, vol. 302, No. 1, pp. L82-L92.

(51) **Int. Cl.**

C12N 9/72 (2006.01)

A61K 9/00 (2006.01)

A61K 38/48 (2006.01)

A61K 38/49 (2006.01)

Vadasz et al. "Update in Acute Lung Injury and Critical Care 2010," *American Journal of Respiratory and Critical Care Medicine*, May 2011, vol. 183, No. 9, pp. 1147-1152.

(52) **U.S. Cl.**

CPC **C12N 9/6459** (2013.01); **A61K 9/0078** (2013.01); **A61K 38/49** (2013.01); **C12N 9/6462** (2013.01); **A61K 38/482** (2013.01); **C12Y 304/21068** (2013.01); **C12Y 304/21073** (2013.01)

Veress et al. "Airway Obstruction Due to Bronchial Vascular Injury after Sulfur Mustard Analog Inhalation." *American Journal of Respiratory and Critical Care Medicine*, 2010, vol. 182, No. 11, pp. 1352-1361.

(58) **Field of Classification Search**

CPC .. A61K 38/54; A61K 36/185; A61K 38/4826; A61K 38/4873; A61K 38/465; A61K 38/47; C12Q 1/37; G01N 33/6896; G01N 2800/52; G01N 2333/976; G01N 2800/2828; C12Y 304/21001; C12Y 304/22002; C12Y 301/01; C12Y 302/01; C12Y 304/00; C12Y 304/21004

Veress et al. "Tissue Plasminogen Activator Prevents Mortality from Sulfur Mustard Analog-Induced Airway Obstruction," *American Journal of Respiratory Cell and Molecular Biology*, Apr. 2013, vol. 48, No. 4, pp. 439-447.

(Continued)

See application file for complete search history.

Primary Examiner — Kade Ariani

(74) *Attorney, Agent, or Firm* — Sheridan Ross P.C.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,612,029 A 3/1997 Bennett et al.
2005/0169908 A1 8/2005 Murakami et al.
2011/0070167 A1 3/2011 Enkhbaatar et al.

(57) **ABSTRACT**

The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.

13 Claims, 24 Drawing Sheets